Flair! i agree with you completely. Inmed seems to be doing nothing at face value but I believe behind the scenes there is a lot going on. These current moves with Colwill and Sazanoff are really important. They tell us that Inmed is looking for the best. They both have amazing resumes and no one realizes how big Sazanoff is with bringing Humera to market. Bott is a small player comparative to her. There is much excitement about the new glaucoma formulation. The "Real" market sees this and everyone sees this as a pump and dump. Time will tell and keep up your great posts and energy! Good luck to all invested here!
News 
Market Data 
Discover 
